Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Evelyn Hearne, Emanuele Amorim Alves, Marie Claire Van Hout & Jean-Paul C. Grund. (2017) Home Manufacture of Drugs: An Online Investigation and a Toxicological Reality Check of Online Discussions on Drug Chemistry. Journal of Psychoactive Drugs 49:4, pages 279-288.
Read now
Read now
Evelyn Hearne & Marie Claire Van Hout. (2016) “Trip-Sitting” in the Black Hole: A Netnographic Study of Dissociation and Indigenous Harm Reduction. Journal of Psychoactive Drugs 48:4, pages 233-242.
Read now
Read now
Articles from other publishers (19)
Matteo Marti, Giuseppe Talani, Cristina Miliano, Sabrine Bilel, Francesca Biggio, Jessica Bratzu, Marco Diana, Maria Antonietta De Luca & Liana Fattore. (2021) New insights into methoxetamine mechanisms of action: Focus on serotonergic 5-HT2 receptors in pharmacological and behavioral effects in the rat. Experimental Neurology 345, pages 113836.
Crossref
Crossref
Kwang‐Hyun Hur, Seong‐Eon Kim, Shi‐Xun Ma, Bo‐Ram Lee, Yong‐Hyun Ko, Jee‐Yeon Seo, Seon‐Kyung Kim, Young‐Jung Kim, Su‐Jeong Sung, Youyoung Lee, Young Hoon Jung, Yong‐Sup Lee, Seok‐Yong Lee & Choon‐Gon Jang. (2021) Methoxphenidine (MXP) induced abnormalities: Addictive and schizophrenia‐related behaviours based on an imbalance of neurochemicals in the brain. British Journal of Pharmacology 178:19, pages 3869-3887.
Crossref
Crossref
Fabrizio Schifano, Stefania Chiappini, Andrea Miuli, John Martin Corkery, Norbert Scherbaum, Flavia Napoletano, Davide Arillotta, Caroline Zangani, Valeria Catalani, Alessandro Vento, Mauro Pettorruso, Giovanni Martinotti, Di Giannantonio Massimo & Amira Guirguis. (2021) New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review. Experimental Neurology 339, pages 113638.
Crossref
Crossref
Stephanie Campos, Ellen Benoit & Eloise Dunlap. (2019) Risk management strategies of synthetic cannabis users. Drugs and Alcohol Today 19:4, pages 270-281.
Crossref
Crossref
Sara Rolando & Franca Beccaria. (2018) This place is like the jungle: discussions about psychoactive substances on a cryptomarket. Drugs and Alcohol Today 18:4, pages 250-261.
Crossref
Crossref
Marie Claire Van Hout, Annemieke Benschop, Michal Bujalski, Katarzyna Dąbrowska, Zsolt Demetrovics, Katalin Felvinczi, Evelyn Hearne, Susana Henriques, Zsuzsa Kaló, Gerrit Kamphausen, Dirk Korf, Joana Paula Silva, Łukasz Wieczorek & Bernd Werse. (2017) Health and Social Problems Associated with Recent Novel Psychoactive Substance (NPS) Use Amongst Marginalised, Nightlife and Online Users in Six European Countries. International Journal of Mental Health and Addiction 16:2, pages 480-495.
Crossref
Crossref
Basile Chrétien, Joanna Bourgine, Léa Hamel Sénécal, Marie Bretaudeau-Deguigne, David Boels, Véronique Lelong-Boulouard & Reynald Le Boisselier. (2018) Severe Serotonin Syndrome in an Autistic New Psychoactive Substance User After Consumption of Pills Containing Methoxphenidine and α-Methyltryptamine. Journal of Clinical Psychopharmacology 38:1, pages 94-96.
Crossref
Crossref
Torsten Passie & Simon D. Brandt. 2018. New Psychoactive Substances. New Psychoactive Substances
69
110
.
Jason Wallach & Simon D. Brandt. 2018. New Psychoactive Substances. New Psychoactive Substances
305
352
.
Marie Claire Van Hout. (2016) The Dynamic Landscape of Novel Psychoactive Substance (NPS) Use in Ireland: Results from an Expert Consultation. International Journal of Mental Health and Addiction 15:5, pages 985-992.
Crossref
Crossref
Noreen D Mdege, Nick Meader, Charlie Lloyd, Steve Parrott & Jim McCambridge. (2017) The Novel Psychoactive Substances in the UK Project: empirical and conceptual review work to produce research recommendations. Public Health Research 5:4, pages 1-138.
Crossref
Crossref
Laurie Anderson, Heidi G Bell, Michael Gilbert, Julie E Davidson, Christina Winter, Monica J Barratt, Beta Win, Jeffery L Painter, Christopher Menone, Jonathan Sayegh & Nabarun Dasgupta. (2017) Using Social Listening Data to Monitor Misuse and Nonmedical Use of Bupropion: A Content Analysis. JMIR Public Health and Surveillance 3:1, pages e6.
Crossref
Crossref
Marie Claire Van Hout & Evelyn Hearne. (2017) New psychoactive substances (NPS) on cryptomarket fora: An exploratory study of characteristics of forum activity between NPS buyers and vendors. International Journal of Drug Policy 40, pages 102-110.
Crossref
Crossref
Shruti Beharry & Simon Gibbons. (2016) An overview of emerging and new psychoactive substances in the United Kingdom. Forensic Science International 267, pages 25-34.
Crossref
Crossref
Moritz Berning & Anita Hardon. (2016) Educated Guesses and Other Ways to Address the Pharmacological Uncertainty of Designer Drugs. Contemporary Drug Problems 43:3, pages 277-292.
Crossref
Crossref
Angus Bancroft & Peter Scott Reid. (2016) Concepts of illicit drug quality among darknet market users: Purity, embodied experience, craft and chemical knowledge. International Journal of Drug Policy 35, pages 42-49.
Crossref
Crossref
Gavin McLaughlin, Noreen Morris, Pierce V. Kavanagh, John D. Power, John O'Brien, Brian Talbot, Simon P. Elliott, Jason Wallach, Khoa Hoang, Hamilton Morris & Simon D. Brandt. (2016)
Test purchase, synthesis, and characterization of 2-methoxydiphenidine (MXP) and differentiation from its
meta
- and
para
-substituted isomers
. Drug Testing and Analysis 8:1, pages 98-109.
Crossref
Crossref
Jolanta B. Zawilska & Dariusz Andrzejczak. (2015) Next generation of novel psychoactive substances on the horizon – A complex problem to face. Drug and Alcohol Dependence 157, pages 1-17.
Crossref
Crossref
Agnieszka Wiesner, Aleksandra Tyl & Jolanta B. Zawilska. (2015) Metoksetamina – nowy związek psychoaktywny („dopalacz”) o silnym działaniu psychodysleptycznym. Alcoholism and Drug Addiction 28:2, pages 131-138.
Crossref
Crossref